| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.087 | 0.009 |
| mRNA | BRD-K71935468 | CTRPv2 | pan-cancer | AAC | -0.1 | 0.009 |
| mRNA | BRD-K97651142 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.01 |
| mRNA | BRD-K27188169:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | 0.081 | 0.01 |
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.14 | 0.01 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.083 | 0.01 |
| mRNA | BRD-K34099515 | CTRPv2 | pan-cancer | AAC | 0.18 | 0.01 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.13 | 0.01 |
| mRNA | BRD-K13185470 | CTRPv2 | pan-cancer | AAC | 0.16 | 0.02 |